A ngiogenesis, the sprouting of new blood vessels from preexisting ones, plays a critical role in various physiological processes, including embryonic development, the female reproductive cycle, wound healing, and organ repair in adults. 1 Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis; it binds to its receptor VEGFR2 (a receptor tyrosine kinase) on the surface of endothelial cells (ECs) and triggers dimerization and transphosphorylation to activate signaling cascades including p44/42 mitogen-activated protein kinases and AKT required for EC migration, proliferation, and tubulogenesis. 2, 3 These VEGF responses can be further promoted by a small number of VEGFR2 coreceptors such as neuropilins, heparan sulfate proteoglycans, CD44, and CD146. [4] [5] [6] [7] [8] [9] However, additional coreceptors for VEGFR2 that regulate VEGF-induced angiogenesis might exist and remain to be discovered. SCUBE2 (Signal peptide-complement protein C1r/C1s, Uegf, and Bmp1 [CUB]-epidermal growth factor [EGF] domain-containing protein 2) is the second member of a small, evolutionarily conserved gene family composed of 3 different genes (SCUBE1, 2, and 3) originally identified from human ECs. 10, 11 The genes encode ≈1000-amino acid polypeptides organized in a modular fashion with 5 protein domains: an NH 2 -terminal signal peptide, 9 tandem repeats of EGF-like motifs, a spacer region, 3 cysteine-rich repeats, and 1 CUB domain at the COOH terminus. These SCUBEs can tether on the cell surface as peripheral membrane proteins by 2 distinct membrane-anchoring mechanisms (ie, electrostatic and lectinglycan interactions) via their spacer region and the cysteinerich repeats, 12 and function as coreceptors for many growth factors. For example, SCUBE1 and SCUBE3 behave as a coreceptor in promoting the signaling activity of bone morphogenetic protein, transforming growth factor-β superfamily members, and fibroblast growth factor. [13] [14] [15] [16] Although many signaling components of these growth factors have been implicated in angiogenesis during development and disease, 17, 18 in vivo vascular phenotypes were not observed in single Scubeknockout mouse strains, [19] [20] [21] which suggests functional compensation among these SCUBE proteins in the angiogenic endothelium during embryonic development and under normal physiological conditions. Besides being expressed in the normal endothelium, 10, 22 SCUBE2 is also highly expressed in hypoxic tumor microvasculature. 22 However, whether SCUBE2 can act as a coreceptor for VEGFR2 and its role in VEGF-induced angiogenesis remain to be determined.
In this study, we investigated whether SCUBE2 is a coreceptor for VEGFR2 and its role in VEGF-induced angiogenesis. SCUBE2 was upregulated by hypoxia-inducible factor-1α (HIF-1α) in response to hypoxic conditions and interacted with VEGFR2 in human ECs, where it acted as a coreceptor with VEGFR2 to facilitate VEGF binding and enhance its downstream signaling, thus promoting VEGFinduced angiogenesis. Endothelial-specific Scube2 knockout (EC-KO) mice showed no defects in vascular development but did show impaired VEGF-induced neovascularization in implanted Matrigel plugs and impaired recovery of blood flow after induced hind-limb ischemia. SCUBE2 may be a novel coreceptor for VEGFR2 that regulates the VEGF-induced tube formation and proliferation of ECs by fine-tuning VEGFR2-mediated signaling, especially during postnatal angiogenesis induced by ischemia or under hypoxic conditions.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

SCUBE2 Is Expressed in Human ECs and Regulates VEGF-Induced EC Proliferation and Tube Formation
We first confirmed SCUBE2 protein expression in human umbilical vein endothelial cells (HUVECs) by immunostaining ( Figure 1A ), flow cytometry ( Figure 1B) , and Western blot analysis ( Figure 1C ). Confocal immunofluorescence staining and flow cytometry revealed SCUBE2 localized partially on the EC membrane ( Figure 1A and 1B) . In addition, protein levels were higher in proliferating, subconfluent ECs than growth-arrested, confluent ECs ( Figure 1C) .
We then investigated a potential role for SCUBE2 in regulating VEGF responses by overexpressing and knocking down SCUBE2 in human ECs. After transduction of recombinant lentivirus encoding the full-length FLAG-tagged SCUBE2 or 2 independent SCUBE2-targeting short hairpin RNAs (shRNA 1 and 2) in HUVECs, the overexpression and knockdown of SCUBE2 were verified by reverse transcription-polymerase chain reaction or Western blot analysis ( Figure 1D and 1G). SCUBE2 overexpression significantly increased ( Figure 1E and 1F) and SCUBE2 knockdown ( Figure 1H and 1I) markedly reduced VEGF-induced EC growth and capillary-like network formation on Matrigel. Together, these data support a role for SCUBE2 in modulating VEGF-induced proliferation and tubulogenesis in HUVECs.
Upregulation of SCUBE2 by HIF-1α in HUVECs
Because hypoxia-induced VEGF expression by HIF-1α is critical for postnatal neovascularization, 1 we then investigated whether endothelial SCUBE2 is also upregulated by a similar mechanism. After 12-hour exposure of HUVECs to hypoxia, the expression of SCUBE2 but not SCUBE1 or SCUBE3 was significantly increased at both mRNA and protein levels, which was concomitant with HIF-1α accumulation (Figure 2A and 2B). Furthermore, ChIP (chromatin immunoprecipitation) assay and promoter mutation analysis confirmed that endogenous HIF-1α could indeed interact with a DNA region that harbors a consensus HIF-binding motif (A/GCTGA) within the SCUBE2 promoter and transactivate SCUBE2 expression in HUVECs with hypoxia treatment ( Figure 2C though 2E) .
Generation of EC-KO Mice
To further investigate the role of endothelial Scube2 on VEGF responses in vivo, we knocked out Scube2 specifically in ECs by crossing mice carrying a conditional Floxed allele of Scube2 (flanking the exons encoding 9 EGF-like repeats, the spacer region, 3 cysteine-rich motifs, and the CUB domain with loxP) 20 with transgenic mice expressing the bacteriophage recombinase Cre under the control of the angiopoietin receptor (Tie2) promoter, which is pan-endothelial expressed ( Figure IA in Flox/− (designated EC-KO) mice ( Figure IB and IC in the online-only Data Supplement).
To determine the endothelial-specific recombination efficiency of the Scube2 Flox allele, primary mouse lung endothelial cells (MLECs) were isolated from control and EC-KO mice. Flow cytometry revealed these cell populations highly enriched in ECs because ≈95% of these cells expressed CD31. In addition, both mRNA and protein levels of Scube2 were efficiently and specifically ablated without obvious compensatory upregulation of Scube1 and Scube3 in EC-KO MLECs ( Figure ID Control and EC-KO mice were recovered at the expected Mendelian ratio and showed the normal pattern of weight gain, so vasculogenesis and angiogenesis were sufficient for normal development. We observed no phenotypic differences in general health and behavior between control and EC-KO animals. EC-KO females animals reproduced normally and had normal litter sizes, which suggested sufficient reproductive angiogenesis to allow for colony propagation. Together, these data suggest that physiological angiogenesis was grossly unaffected by endothelial inactivation of Scube2.
Responses to Exogenous VEGF and Adult Angiogenesis Are Impaired in Scube2 EC-KO Mice
To explore the potential function of endothelial Scube2 in VEGF-stimulated angiogenesis in vivo, we used Matrigel plug assay with Matrigel mixed with VEGF (+) or saline (−) administered subcutaneously to age-and sex-matched EC-KO and control mice with recovery 7 days later ( Figure 3 ). On gross examination, Matrigel plugs containing VEGF from control mice were reddish-brown ( Figure 3A ). However, plugs containing VEGF from EC-KO mice were paler than control plugs ( Figure 3A ). Consistently, total hemoglobin content, a measure of intact vessel formation associated with the amount of newly formed capillary network, in VEGFcontaining Matrigel plugs was reduced ≈50% for EC-KO mice ( Figure 3B ). To ensure that this hemoglobin difference was caused by reduced microvasculature density, blood vessel infiltration in implants was quantified by immunostaining with anti-CD31 antibody (a marker of endothelia; Figure 3C and 3D). In contrast to Matrigel-implanted control mice, implanted EC-KO mice showed decreased vascularization, even in saline-containing plugs ( Figure 3C ). Furthermore, the microvascular density of VEGF-containing plugs was lower by 50% in EC-KO than in control mice ( Figure 3D ), and no large vascular tubes were seen ( Figure 3C ), which suggests that the VEGF-induced adult angiogenic response depends on endothelial Scube2 in vivo.
To further evaluate the proangiogenic effect of endothelial Scube2, we used a second adult neovascularization model (ie, hind-limb ischemia): the common femoral artery was ligated in control and EC-KO mice, and blood flow as well as vascular regeneration and angiogenesis were monitored over time by laser Doppler imaging and anti-CD31 immunostaining, respectively. Laser-Doppler analyses revealed a similar degree of reduced blood flow in ligated limbs of control and EC-KO animals after surgery as compared with nonligated contralateral limbs ( Figure 3E and 3F), which indicates comparable postsurgery ischemia in both strains. In control mice, blood flow recovered to almost baseline levels by 21 days after surgery. However, blood flow recovery was significantly impaired in EC-KO animals ( Figure 3E and 3F) . Consistently, histology of the gastrocnemius (calf) muscle showed lower anti-CD31-positive capillary density induced by ligation in EC-KO than that in control mice at 21 days ( Figure 3G and 3H) . Therefore, functional Scube2 may be required in the endothelium for revascularization after ischemia induced by femoral artery ligation.
SCUBE2 Colocalizes and Interacts With VEGFR2 and Potentiates VEGF Binding to VEGFR2 in HUVECs
Because SCUBE2 can regulate VEGF responses both in vitro and in vivo (Figures 1 and 3) and SCUBE proteins can function as coreceptors for signaling receptor serine/threonine kinases or receptor tyrosine kinases, [13] [14] [15] [16] we examined whether SCUBE2 colocalizes and interacts with VEGFR2 in HUVECs. Confocal microscopy and coimmunoprecipitation experiments indeed revealed that VEGF promotes their colocalization at the plasma membrane and enhances the association of SCUBE2 with VEGFR2, peaking at 10 minutes after VEGF stimulation in HUVECs ( Figure 4A To evaluate whether SCUBE2 could indeed increase VEGF binding to VEGFR2, we first produced a functional AP-VEGF Figure 4C ). Together, these data suggest that SCUBE2 acts as a coreceptor for VEGFR2 and potentiates VEGF binding to VEGFR2 ( Figure 4D ).
SCUBE2 Modulates VEGFR2 Phosphorylation and Downstream Signaling in HUVECs
We next investigated whether SCUBE2 facilitates VEGFactivation signals in HUVECs. To this end, we used VEGF as a stimulator and SCUBE2 shRNA knockdown or SCUBE2 overexpression to evaluate the function of SCUBE2 on VEGFinduced signaling. VEGF could induce VEGFR2 Tyr1059 phosphorylation, the p44/42 mitogen-activated protein kinase signaling cascade, and AKT activation. However, SCUBE2 shRNA knockdown reduced ( Figure 5A and 5B) and SCUBE2 overexpression ( Figure 5C and 5D) enhanced VEGF-induced VEGFR2 phosphorylation, the p44/42 mitogen-activated protein kinase signaling cascade, and AKT activation. Our data strongly indicate that as a VEGFR2 coreceptor, SCUBE2 is involved in regulating VEGF-induced VEGFR2 downstream signals in HUVECs. We have determined the phosphorylation status of SCUBE2 on treatment of VEGF in HUVECs. After VEGF stimulation, anti-SCUBE2 immunoprecipitates were blotted with anti-phosphotyrosine or anti-phosphoserine/threonine (p-Ser/Thr) pan-specific antibody, respectively. SCUBE2 seems unphosphorylated on treatment with VEGF ≤30 minutes. However, further phosphoproteomic analysis will be needed to verify whether or not SCUBE2 is phosphorylated after VEGF stimulation ( Figure VII in the online-only Data Supplement).
Scube2 Modulates VEGF Signaling in MLECs
Similar to our knockdown experiments in HUVECs ( Figure 1G through 1I) , VEGF-induced cell proliferation and tube formation were markedly attenuated in EC-KO MLECs as compared with control MLECs (Figure 6A and 6B) . We further assessed the effect of endothelial Scube2 gene deletion on VEGF-induced signaling. We stimulated control and EC-KO MLECs with 50 ng/mL VEGF for 0, 10, 20, and 30 minutes. In agreement with SCUBE2 shRNA knockdown in HUVECs, VEGF signaling, determined by phosphorylation of VEGFR2, p44/42 mitogen-activated protein kinase, and AKT, was markedly lower in EC-KO than that in control MLECs ( Figure 6C and 6D) .
Decreased Microvessel Outgrowth From Aortic Explant of Scube2 EC-KO Mice
We further investigate the role of SCUBE2 in angiogenesis using the ex vivo aortic ring sporting assay, in which we compared the angiogenic potential of aortic fragments derived from control and EC-KO mice. The aortic rings, isolated from control and EC-KO mice, were treated with PBS or VEGF, and the angiogenic response was determined for each individual aortic ring explant by quantifying the number of growing microvessels and by measuring the total length occupied by the newly formed microvessels. Quantification of the number of the tube-like structures (sprouts) and of the length of sprouts in response to VEGF (30 ng/mL) at 5 days showed a significant decrease of both parameters in EC-KO compared with control aortic rings ( Figure 6E and 6F) . Therefore, these ex vivo results confirm in vitro data and support the role of SCUBE2 in VEGFR2-mediated angiogenesis.
Discussion
Although SCUBE2 was originally identified as an endothelial gene more than a decade ago, 10 its functional relevance in vascular biology during physiological or pathological conditions has not been reported. Even with global inactivation of Scube2, we did not observe abnormalities in vasculogenesis and angiogenesis during mouse embryonic development, 20 which suggests possible gene and functional redundancy compensated by Scube1 and Scube3 genes. Alternatively, the VEGF signaling levels are sufficient so that any potential enhancement by Scube2 during embryonic vascular development is redundant. In the present study, we show that hypoxia mediated HIF-1α-upregulated SCUBE2 at the EC surface, which could interact directly with VEGFR2 and function as a coreceptor to facilitate VEGF binding and VEGF-induced signal transduction, thus playing a critical role in adult angiogenesis.
Several lines of evidence suggest the role of SCUBE2 as a coreceptor for VEGFR2. First, SCUBE2 physically associates with VEGFR2 in a complex in overexpressed HEK-293T cells and in human ECs endogenously expressing both molecules. Second, SCUBE2 co-operates with VEGF and potentiates its binding to VEGFR2 to enhance VEGF-induced VEGFR2 phosphorylation and downstream signaling, which results in EC proliferation and capillary network formation. Moreover, VEGF-induced cellular responses and signals in HUVECs could be genetically enhanced by overexpression of SCUBE2 and suppressed by SCUBE2 knockout (EC-KO) and shRNAmediated knockdown. Besides Scube2-KO mice, many other KO mouse strains also show normal vascular development but impaired postnatal angiogenesis and vascular remodeling. For instance, deficiency of a neuropilin-related transmembrane 25 or an immunoglobulin-like cell adhesion molecule 26 in mice did not affect embryonic vascular formation but impaired postnatal angiogenesis after ischemia. Although why the absence of these genes is not compensated in ischemia-induced adulthood angiogenesis is unknown, we noted that SCUBE2 but not SCUBE1 or 3 was specifically upregulated by HIF-1α in HUVECs under hypoxia (Figure 2 ). This unique hypoxic induction of SCUBE2 might explain in part its distinctive role in regulating blood flow recovery after hind-limb ischemia ( Figure 3) .
Although several other VEGFR2 coreceptors such as neuropilins 6,7 and CD46v6 5 have been implicated in VEGFR2 signaling and angiogenesis, unlike neuropilins, which interact with VEGFR2 and depend on VEGF treatment, 6,7 SCUBE2 and VEGFR2 were preformed in a complex independent of VEGF stimulation in our study. Different VEGFR2 coreceptors may potentiate VEGF signal transduction by distinct mechanisms that may elicit divergent downstream signals, thereby leading to different EC functions depending on the disease status. Therefore, further elucidating the molecular functions of these coreceptors in VEGF-mediated angiogenesis is important.
Another interesting point is that membrane tethering of SCUBE proteins was mediated at least by a polycationic stretch in their spacer region via electrostatic interactions with anionic heparin sulfate proteoglycans expressed on the cell surface. 12, 27 Because VEGF has been described as a heparinbinding growth factor 28 and shown to bind to heparin sulfate proteoglycans, 4 a full-scale postnatal angiogenic response may involve co-operation between SCUBE2, heparin sulfate proteoglycans, VEGFR2, and VEGF on the EC surface.
Of note, we and others have recently found that SCUBE2 can positively regulate sonic hedgehog signaling, 20, [29] [30] [31] which has been implicated in neovessel formation. 32 In addition, endothelial SCUBE2 might collaborate with VE-cadherin (a major adhesive protein of adherens junctions in ECs) essential in supporting vascular stability and promoting angiogenesis 33 because epithelial SCUBE2 could indeed associate with E-cadherin (a major adhesive protein of adherens junctions in epithelium) in maintaining and driving the epithelial molecular phenotype. 34 Therefore, the involvement of SCUBE2 in angiogenesis was not restricted to the action of VEGF, although further studies are needed to clarify whether SCUBE2 participates in postnatal angiogenesis mediated by sonic hedgehog or VE-cadherin signaling.
Our study revealed SCUBE2 as a novel VEGFR2 coreceptor that regulates VEGF-induced tube formation and proliferation of ECs by fine-tuning VEGFR2-mediated signaling. However, whether SCUBE2 has clinical importance in the pathogenesis of various angiogenesis-related diseases such as atherosclerosis, diabetic retinopathy, and age-related macular degeneration is unknown. In addition to its expression in normal organ ECs, SCUBE2 is also highly expressed in the ECs of numerous types of human carcinomas and xenografted tumors (Y.-C. Lin et al., unpublished data, 2016) . Although further studies are required to validate whether endothelial SCUBE2 is involved in tumor angiogenesis, SCUBE2 may be a promising target molecule for cancer therapy because of its antiangiogenic effect of SCUBE2 inactivation. Pharmacological blockade of endothelial SCUBE2 may represent a novel therapeutic strategy for angiogenesis-related disorders. Figure 6 Continued. signaling in MLECs (C) and quantification (D) of VEGF-induced phosphorylation of VEGFR2 Tyr1059, p44/42 MAPK Thr202/Tyr204, and AKT Ser473 in control and EC-KO MLECs. Data are mean±SD from 3 independent experiments. *P<0.05; **P<0.01 compared with control. E, Photomicrographs show the angiogenic response of 5-d culture collagen-embedded thoracic aorta ring explants from control and EC-KO mice. Scale bar=1 mm. F, Quantification of the number and length of microvessel sprouts. The angiogenic response was determined for each individual aortic ring explant by quantifying the number of growing microvessels (top) and by measuring the total length occupied by the newly formed microvessels (bottom).
